Plexins are transmembrane protein receptors for semaphorin molecules. These molecules are involved in numerous cellular activities related to cell proliferation, adhesion along with the basement membrane, cellular motility and invasive capability. All nine members of Plexins identified in vertebrates have been grouped into subclasses, termed Plexin-A, Plexin-B, Plexin-C and Plexin-D. Plexin-B consists of three members, namely Plexin-B1, Plexin-B2 and Plexin-B3. Plexin-B1 functionally interacts with Sema4A (Yukawa et al., 2010) and can also form heterodimer with Plexin-B2 for Sema4A binding (Nkyimbeng-Takwi et al., 2011). Plexin-B2 binds with Sema4C. Plexin-B3 mediates interaction with both Sema4G and Sema5A. Some semaphorines exist in a membrane-bound form only, whereas other family members can be found in tissues/fluids in both secreted and membrane-bound forms. This ligand-receptor interaction between sema4D and Plexin-B1 indicated in different signaling pathways results in many intriguing and interesting findings, highlighting its importance in both physiology and pathology. Apart from bidirectional signaling among these molecules, the involvement of Plexin-B1 in the processes described here directly involves a bidirectional singaling between Sema4Dand Plexin-B1. Being a high affinity receptor for both Sema4A and Sema4D, the role played by Plexin-B1 in cancer progression, metastasis and angiogenesis is still an area requiring further research. Activation of Sema4D mediated downstream effectors is largely influenced by cross talk of Plexin-B1 with other molecules, such as Her-2 and Met. In this review, all findings regarding Plexin-B1 upstream and downstream regulation and its putative involvement in relation to the ultimate fate of cancer cells are discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14670/HH-29.151 | DOI Listing |
Cancer Treat Rev
January 2025
Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, United States. Electronic address:
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.
Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).
Ann Intern Med
January 2025
Department of Medicine, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (S.M.J.A., M.L.).
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in the United States. It is characterized by steatosis in the liver and is potentially reversible. Risk factors include obesity, type 2 mellitus, and other metabolic disorders.
View Article and Find Full Text PDFJ Clin Oncol
January 2025
George M. Rodgers, MD, PhD, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; and Jeffrey A. Gilreath, PharmD, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, Department of Pharmacy, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
J Clin Oncol
January 2025
Shun Lu, MD, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; and Jiong Wu, MD, Cancer Hospital, Fudan University, Shanghai, China.
Adv Sci (Weinh)
January 2025
Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), Ulsan, 44919, South Korea.
Current in vitro models of 3D tumor spheroids within the microenvironment have emerged as promising tools for understanding tumor progression and potential drug responses. However, creating spheroids with functional vasculature remains challenging in a controlled and high-throughput manner. Herein, a novel open 3D-microarray platform is presented for a spheroid-endothelium interaction (ODSEI) chip, capable of arraying more than 1000 spheroids on top of the vasculature, compartmentalized for single spheroid-level analysis of drug resistance, and allows for the extraction of specific spheroids for further analysis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!